Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of IPI-145 plus rituximab vs rituximab in previously treated follicular lymphoma
2013-002406-31Phase 3Completed
- Sponsor
- Infinity Pharmaceuticals, Inc.
- Start
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in follicular lymphoma (FL) and non-Hodgkin lymphoma (NHL) comparing Duvelisib + rituximab with Placebo + rituximab (2 arms). Primary endpoint: Progression-free survival. Started Jul 2014; status: completed.
02
Drugs
duvelisib
03
Conditions
follicular lymphoma (FL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on 2013-002406-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002406-31.